Abstract

Evercore Partners will report its quarterly results before the market open on July 29, 2026 (Pre-Mkt), and this preview synthesizes last quarter’s results with current-quarter forecasts to frame what matters for revenue, margins, net profit, and adjusted EPS.

Market Forecast

Consensus expects Evercore Partners to deliver revenue of 925.60 million US dollars this quarter, up 32.50% year over year, adjusted EPS of 2.77, up 55.28% year over year, and EBIT of 171.88 million US dollars, up 68.36% year over year; margin forecasts are not broadly disclosed by the market at this time. The company’s main business is advisory-driven investment banking, whose fee conversion and deal closings are expected to guide near‑term top‑line and earnings, with a sequential step‑down from last quarter’s unusually strong base already reflected in consensus. The most promising driver remains investment banking, which generated 1.36 billion US dollars last quarter as the company’s overall revenue grew 100.25% year over year, setting a high bar for execution while leaving room for positive surprise if close rates stay firm.

Last Quarter Review

Evercore Partners posted revenue of 1.40 billion US dollars in the previous quarter, up 100.25% year over year, with a gross profit margin of 94.86%, net profit attributable to shareholders of 301.00 million US dollars, a net profit margin of 21.65%, and adjusted EPS of 7.53, up 115.76% year over year. Results reflected robust operating leverage as fee growth translated into higher profitability and strong per‑share earnings compared with the prior year’s baseline. Within the business mix, investment banking contributed 1.36 billion US dollars, supported by company‑wide revenue growth of 100.25% year over year, while asset management and management fees and other revenues added 22.64 million and 15.36 million US dollars, respectively.

Current Quarter Outlook

Advisory revenue cadence and fee conversion

The defining question for this quarter is how advisory fees convert from announced mandates into closed transactions and billable revenue, given that last quarter’s 1.40 billion US dollars was powered by a surge in closings. Consensus embeds a more normal run‑rate, with revenue at 925.60 million US dollars and EBIT at 171.88 million US dollars, recognizing that deal timing drives volatility and that the prior quarter created a tough sequential comparison. Watch for qualitative commentary on the pace of signings and closings, the distribution of advisory fees across larger transactions versus middle‑market engagements, and any color on fee rates and retainer trends that could influence near‑term revenue recognition.

A second vector is the mix inside investment banking between pure strategic advisory and other fee lines such as placements and underwriting. While the company’s segment data show investment banking dominated the revenue base last quarter, the balance among sub‑activities can move quarterly earnings by shifting both the level and timing of revenue. If strategic advisory maintained strong close rates through the quarter, the setup favors positive surprise; if closings slipped into the next quarter, results could skew toward the lower end of expectations even if the pipeline remains active. Management’s language around the quarter‑to‑date dialogue with clients, the size and quality of mandates, and the status of sign‑to‑close cycles will therefore be essential for interpreting how the remainder of the year may track.

Margins will hinge on the compensation and non‑compensation cost lines relative to revenue. The last quarter’s 94.86% gross margin and 21.65% net margin showed healthy conversion of revenue to profit at the company level. This quarter, investors will focus on how compensation accruals flex with revenue, the trajectory of non‑compensation expenses tied to travel, technology, and occupancy, and whether the firm signals any change in expense discipline as it balances senior hiring with profitability. Commentary on expected tax rate and any unusual items also matters for translating operating results into adjusted EPS, where consensus stands at 2.77 for the quarter.

Healthcare and industrial advisory as incremental growth vectors

Recent senior‑level additions reinforce the build‑out of sector coverage that can support future fee generation. Eric Rabinowitz joined as Senior Managing Director in Healthcare Investment Banking, bringing two decades of experience across large biopharma transactions. Healthcare mandates tend to be complex and can sustain a pipeline of high‑value strategic reviews; if integration is smooth and client dialogues materialize into mandates, the contribution could appear first in signings and grow into closings over the next few quarters.

Similarly, the appointment of Chris Connelly as Senior Managing Director in the Industrial Investment Banking Group indicates continued investment in verticals that have historically generated a steady cadence of corporate actions. Senior banker additions often have a lag before translating into measurable revenue, as relationship re‑engagement, mandate origination, and regulatory processes unfold. Nonetheless, the near‑term signal is constructive for coverage depth and competitive engagement on sizeable transactions in healthcare and industrial segments, which can broaden the firm’s mix and support fee durability through the cycle.

From a quarter‑specific perspective, the primary impact of these hires in the period being reported is likely felt in the forward pipeline rather than the just‑completed revenue. However, any color in management’s prepared remarks or Q&A regarding initial client engagement, early mandate wins, or the state of the healthcare and industrial backlogs will help investors gauge whether the expected uplift to advisory fees could arrive in the back half of the year. The presence of seasoned leaders can also aid pricing power and improve the probability of winning contested mandates, with positive implications for both revenue and margin quality over time.

What will move the stock this quarter

The magnitude of the EPS delta versus the 2.77 consensus and the revenue delta versus 925.60 million US dollars are likely the central drivers of the stock’s immediate reaction. A beat driven by strong close rates and disciplined cost control would typically be rewarded, while a miss caused by closings slipping into subsequent periods might be discounted if management provides credible evidence of near‑term conversion. Because advisory revenue recognition is inherently event‑driven, even modest deviations in the timing of a handful of large transactions can shift quarterly outcomes disproportionately.

Beyond the headline numbers, investors will parse margin commentary closely. Signals that compensation expense is flexing in line with revenue and that non‑compensation expenses remain contained can sustain confidence in earnings power even if revenue proves choppy quarter to quarter. Consistency in net margin around the prior quarter’s 21.65% is not a base case given the sequential revenue reset; however, reaffirmation of cost discipline and visibility into the balance of the year can mitigate concerns about volatility and support multiple stability.

Finally, qualitative guidance on the pipeline and the conversion outlook will set the tone for the next leg. Management’s remarks on signed deals yet to close, sector hotspots within the firm’s portfolio, and the breadth of ongoing strategic dialogues will help investors calibrate whether the current consensus trajectory for revenue and EPS across the year remains conservative or ambitious. Updates on capital deployment, including share repurchases and dividend policy, can also influence the stock’s risk‑reward by shaping per‑share earnings and signaling confidence in forward cash generation.

Analyst Opinions

Bullish versus bearish ratio for directional views in the last six months: bullish 100%, bearish 0%. Analysts tracking the name point to constructive expectations around near‑term execution: an aggregated read shows an average rating of overweight with a mean price target of 388.11 US dollars, and a recent preview characterized institutional expectations as optimistic for a 32.50% year‑over‑year revenue increase this quarter alongside a 55.28% rise in adjusted EPS and a 68.36% increase in EBIT. The positive stance centers on the idea that consensus already contemplates a normalization from last quarter’s outsized base, leaving room for upside if fee conversion remains resilient.

Within this broadly positive framing, selected institutions have adjusted their views in ways that align with a constructive outlook, even when maintaining neutral ratings. One notable update raised the price target to 350.00 US dollars while keeping a neutral stance, which underscores a measured but favorable assessment of execution prospects and earnings durability. Another update trimmed a price target to the mid‑370s while reiterating an equalweight posture, which, in context, still implies confidence in the company’s ability to sustain performance near current expectations given the volatile patterns inherent to advisory revenue.

The market’s majority view heading into July 29, 2026 is that the company is positioned to meet or modestly exceed the consensus path on revenue and EPS, with the balance of evidence leaning toward constructive fee conversion, stable cost discipline, and continued contribution from investment banking as the core engine. Bullish analysts emphasize that the quarter’s setup benefits from a realistic baseline, given the sequential step‑down embedded in forecasts from 1.40 billion US dollars last quarter to 925.60 million US dollars this quarter, and that even incremental beats on closings or margin execution could translate into a meaningful per‑share earnings surprise relative to the 2.77 consensus. In this context, the upcoming report’s most influential signals will likely be management’s commentary on the size and quality of the backlog, early evidence of contribution from newly hired senior bankers in healthcare and industrials, and guidance on expense flexibility across compensation and non‑compensation lines for the second half of the year.